Evidence map›Paper›PMID 39700136›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2024

Alveolar macrophages are early targets of mumps virus.

Aum R Patel, Amit Garg, Haylen T Rosberger, Shreyas Kowdle, Rebecca A Reis, Justin J Frere, Megan N Januska, Gbalekan Dawodu, Estefania Valencia, Min-Chi Yang and 6 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Aum R PatelDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0002-7247-0349
Amit GargDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0002-6774-3648
Haylen T RosbergerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Shreyas KowdleDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Rebecca A ReisDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0002-6118-1509
Justin J FrereDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Megan N JanuskaDepartment of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0003-1419-6449
Gbalekan DawoduThoracic Surgery Department, Icahn School of Medicine at Mount Sinai, Mount Sinai Health System, New York, NY 10029.
Estefania ValenciaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Min-Chi YangDepartment of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Christian S StevensDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0003-2472-6984
Vishal N RaoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Griffin D HaasDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Ya-Wen ChenDepartment of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0003-2382-8444
Benhur LeeDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0003-0760-1709
Jean K LimDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.

Funding

Project 6 - Development of Antivirals against AlphavirusesU19AI171403 · NIAID · EMORY UNIVERSITY · PI George Robert Painter, Richard K. Plemper · 2022 to 2026
$59.7M
Mount Sinai Medical Scientist Training ProgramT32GM146636 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Talia H Swartz · 2022 to 2026
$6.8M
HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) R01AI188431HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID) U19AI171403NIAID NIH HHS R01 AI188431NIAID NIH HHS U19 AI171403NIGMS NIH HHS T32 GM146636U.S. Department of Defense (DOD) PR192188
6 · The paper itself

Abstract

Formerly a common childhood pathogen, mumps virus (MuV) remains active worldwide, despite relatively high vaccine coverage. MuV is thought to infect the upper respiratory tract before disseminating to other organs; however, the early cellular targets of MuV in vivo are unknown. To address this, we generated a green fluorescent protein (GFP)-tagged vaccine strain (JL5) of MuV to infect leukocytic cell lines and found that replication was greatest in monocytes. Infection of peripheral blood mononuclear cells (PBMCs) also showed that both JL5 and a circulating strain of MuV (Iowa 2006; genotype G), preferentially infected monocytes. Further, monocyte-derived macrophages showed high susceptibility to MuV, with genotype G infecting macrophages to a much greater extent. While mice are generally resistant to MuV infection, we inoculated immunocompetent Rosa26-tdTomato mice intranasally with a GFP and Cre recombinase tagged MuV to determine whether monocytes/macrophages are important targets in vivo. We observed a small population of tdTomato

Indexed as

Macrophages, AlveolarMumpsMumps virusAnimalsFemaleGreen Fluorescent ProteinsHumansLeukocytes, MononuclearLungMiceMice, Inbred C57BLMonocytesVirus ReplicationGreen Fluorescent Proteinsentrylungmousemyeloidpathogenesis

Identifiers

PMID39700136
PMCPMC11670124

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.